EP3082924B1 - Interface de patient - Google Patents

Interface de patient Download PDF

Info

Publication number
EP3082924B1
EP3082924B1 EP14811920.9A EP14811920A EP3082924B1 EP 3082924 B1 EP3082924 B1 EP 3082924B1 EP 14811920 A EP14811920 A EP 14811920A EP 3082924 B1 EP3082924 B1 EP 3082924B1
Authority
EP
European Patent Office
Prior art keywords
patient interface
indicator
interface according
mask
hydrophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP14811920.9A
Other languages
German (de)
English (en)
Other versions
EP3082924A1 (fr
Inventor
Mareike Klee
Nicolaas Petrus Willard
Joyce Van Zanten
Lutz Christian GERHARDT
Veena MOHAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips NV filed Critical Koninklijke Philips NV
Priority to EP14811920.9A priority Critical patent/EP3082924B1/fr
Publication of EP3082924A1 publication Critical patent/EP3082924A1/fr
Application granted granted Critical
Publication of EP3082924B1 publication Critical patent/EP3082924B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A61M16/0605—Means for improving the adaptation of the mask to the patient
    • A61M16/0616—Means for improving the adaptation of the mask to the patient with face sealing means comprising a flap or membrane projecting inwards, such that sealing increases with increasing inhalation gas pressure
    • A61M16/0622—Means for improving the adaptation of the mask to the patient with face sealing means comprising a flap or membrane projecting inwards, such that sealing increases with increasing inhalation gas pressure having an underlying cushion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A61M16/0605—Means for improving the adaptation of the mask to the patient
    • A61M16/0633—Means for improving the adaptation of the mask to the patient with forehead support
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A61M16/0605—Means for improving the adaptation of the mask to the patient
    • A61M16/0616—Means for improving the adaptation of the mask to the patient with face sealing means comprising a flap or membrane projecting inwards, such that sealing increases with increasing inhalation gas pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/06—Respiratory or anaesthetic masks
    • A61M16/0683—Holding devices therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0205—Materials having antiseptic or antimicrobial properties, e.g. silver compounds, rubber with sterilising agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/02—General characteristics of the apparatus characterised by a particular materials
    • A61M2205/0227—Materials having sensing or indicating function, e.g. indicating a pressure increase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/13—General characteristics of the apparatus with means for the detection of operative contact with patient, e.g. lip sensor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A61M2205/584—Means for facilitating use, e.g. by people with impaired vision by visual feedback having a color code

Definitions

  • the present invention relates to a member of a patient interface which indicates (preferably visually) a user that the member and/or the patient interface needs to be replaced due to long-term usage and related functionality changes of materials. Further, the present invention relates to a patient interface including such a member.
  • Patient interfaces such as masks in pressure support systems, are used for delivering gas to a user.
  • gases like air, cleaned air, oxygen, or any modification thereof are submitted to the user (also referred to as patient) via the patient interface in a pressurized or unpressurized way.
  • OSA obstructive sleep apnea or obstructive sleep apnea syndrome
  • OSA is usually caused by an obstruction of the upper airway. It is characterized by repetitive pauses in breathing during sleep and is usually associated with a reduction in blood oxygen saturation. These pauses in breathing, called apneas, typically last 20 to 40 seconds.
  • the obstruction of the upper airway is usually caused by reduced muscle tonus of the body that occurs during sleep.
  • the human airway is composed of walls of soft tissue which can collapse and thereby obstruct breathing during sleep. Tongue tissue moves towards the back of the throat during sleep and thereby blocks the air passages. OSA is therefore commonly accompanied with snoring.
  • CPAP Continuous Positive Airway Pressure
  • BiPositive Airway Pressure Bi-Positive Airway Pressure
  • a patient interface e.g. a face mask
  • CPAP Continuous Positive Airway Pressure
  • BiPAP Bi-Positive Airway Pressure
  • the patient interface In order to guarantee a reliable operation of the device, the patient interface needs to closely fit on the patient's face to provide an air-tight seal at the mask-to-face interface.
  • the patient interface is worn using a head gear with straps that go around the back of the patient's head.
  • the patient interface or mask in practice usually comprises a soft cushion that is used as mask-to-patient interface, i.e. that contacts the face of the patient when the mask is worn, as well as it usually comprises a so-called mask shell building a rigid or semi-rigid holding structure for holding the cushion in place and for supplying mechanical stability to the patient interface.
  • the cushion usually comprises one or more pads made of gel or silicone or any other soft material in order to increase the patient comfort and guarantee a soft feeling on the patient's face.
  • the latter-mentioned mask shell usually also comprises a hose interface that is adapted for connecting the air supplying hose to the mask. Depending on the type of the mask, it may also comprise a mechanism with an additional cushion support on the forehead to balance the forces put by the mask around the airway entry features of the human face.
  • the patient interface may be disassembled into different parts in order to ease the cleaning of the patient interface.
  • parts of the patient interface such as cushions, have to be replaced frequently as they can wear out as a consequence of material degradation over time.
  • These parts of the patient interface which are in immediate contact with the skin may contain compounds having a predefined functionality such as compounds assisting in avoiding skin infection or skin irritations, in particular redness, or skin damage/breakdown due to regular long-term usage of the patient interface. Examples of these compounds comprise moisture uptake means and anti microbial agents. These compounds are however subjected to loss and/or decomposition with the consequence that the mask or parts thereof require substitution.
  • US 2009/0199857 A1 informs about such a mask including a patient interface and a reminder system provided to the patient interface.
  • the reminders may be based on chemicals and changes in appearance on parts of the mask itself. Chemicals may be provided indicating after a predetermined period of time that replacement is required.
  • US 4,488,547 A discloses a surgical mask which changes color to signal a significant loss of bacterial filtration efficiency due to moisture accumulation.
  • Said mask has a layer of a bacterial filtration material of a first color.
  • a hygroscopic material partially covers a surface of said layer of filtration material and serves for the absorption of water from respired air. Absorption causes said hydroscopic material to change color to a second color not identical to said first color. Color change from said first color to said second color indicates that replacement of the mask is required.
  • US 2010/0018534 A1 refers to a patient interface, wherein the interface material may be made of a foam acting as heat and moisture exchanger. It is further mentioned that the foam structure may have a certain usage life or lifespan. The foam structure may include an end-of-life indicator to indicate that the end of usage life has been reached.
  • US 4,155,358 pertains to a disposable valveless chemical cartridge respirator for filtration of vinyl chloride monomer.
  • the cartridge has an end of service life indicator.
  • the indicator system is based on potassium permanganate changing its color due to the reductive influence of vinyl chloride.
  • a member for patient interfaces comprises at least one functional material having a predefined functionality and at least one indicator, wherein concentration of said at least one indicator in said member correlates with the predefined functionality of said at least one functional material, wherein said at least one functional material and said at least one indicator are arranged in a skin contacting material.
  • the at least one functional material having a predefined functionality comprises a moisture uptake means and/or an anti microbial agent.
  • WO2012/131001 discloses a member for a patient interface comprising a matrix material having at least 2 components. One of these components is gradually released from the surface of the member.
  • a patient interface for delivering gas to a user is presented, said patient interface comprises the present member.
  • the invention therefore overcomes the above-mentioned disadvantages by providing a member or a patient interface comprising such a member wherein one or more indicators, such as color indicators, are employed.
  • concentration(s) of said one or more indicators correlate(s) with the predefined functionality of said at least one functional material.
  • the present inventors have found that the loss of the predefined functionality of a material, such as an active compound, by e.g. washing out or decomposition may be easily correlated to the concentration of the indicator.
  • a colored indicator is employed as indicator, a color change indicates when the predefined functionality is either completely or partially lost.
  • color wheels or color diagrams may be provided permitting the user to assess wear out of the member qualitatively by comparison of the actual color of the member with the colors of the color wheel or colored diagram.
  • This permits in turn immediate assessment of the condition of the member/ patient interface by indicating for example that the device is either new or needs replacement.
  • It is even possible to quantitatively indicate the remaining span of life by indicating a time specification, such as several days or weeks. This may be obtained by assigning the actual color of the indicator to a color wheel or a colored diagram containing indications referring to a time specification which may be indicated in terms of days or weeks.
  • the time specification indicated may be also in form of a time frame.
  • a member as used herein may be understood as any component of a patient interface. It particularly addresses to components which are either in direct contact with the skin of the user upon wearing the same or in close vicinity thereto.
  • the member may be for instance the cushion or the skin contacting material (SCM) formed or made thereon.
  • SCM skin contacting material
  • the member may also correspond to the mask shell and/or forehead support.
  • the member may be processed by a variety of materials including hydrophilic silicones, for instance Elastosil LR3 004/40 filled with alpha olefin sulfonate. It will be appreciated that the member is not limited to patient interfaces but may be also employed in other body-worn devices such as head sets.
  • a functional material having a predefined functionality addresses essentially each kind of active compounds, such as drugs, prodrugs, or skin oils, including of which may be beneficial for the user upon wearing the member/ patient interface.
  • the functional material may be a compound added to the material forming said member.
  • Examples of such functional materials comprise inter alia an alpha olefin sulfonate or a quorum sensing inhibitor.
  • Said functional materials may be in form of molecules which may be embedded in the material forming the member.
  • the moisture uptake means can be provided by a variety of materials or material systems such as a hydrophilic material that absorbs water, a hydrophilic material formed with capillaries which take up water, etc.
  • the take up of water into the material can result in softening or weakening of the material and the support material has the purpose of supporting such weakened material.
  • the moisture uptake means can comprise a hydrophilic material or a hydrophobic material depending on how it is structured and used.
  • the hydrophilic material may be a textile integrated in the contact structure. Preferably such a material is adapted so that said textile at said skin surface of a user is crease-free and/or leak- free.
  • the hydrophilic material can be a rubber material that takes up at least 5% by weight of water, preferably more that 10% by weight of water and particularly preferably more than 40% up to 120 % by weight of water, or up to 200% or up to 250% or up to 500% by weight of water after immersion in demineralized water at room temperature for a sufficient time such as 5 days or more to reach saturation. It is expected that with increasing water absorption the mechanical properties may be reduced such that a support material is not only necessary but must be designed in a form that will stabilize the hydrophilic material.
  • the inclusion of moisture uptake means generally exhibit the problem that regular washing, usually at least once every day, of the patient interface, in particular the parts contacting the skin, i.e. cushion/member or at least the member skin contact area, is required.
  • a timeframe of typically 60-180 days and standard washing procedures provided by the manufacturer the moisture controlling properties of a patient interface made of hydrophilic polymers with the hydrophilic material mixed into the polymer are nearly lost.
  • the capillaries in a patient interface made of hydrophobic material are suspected to be covered with sebum. This results in the effect that the patient has increase moisture accumulation underneath the cushion or member of the mask and chance of increased red mark formation which may be effectively prevented by using the present patient interface or member for a patient interface.
  • anti microbial agents are intended to address contamination caused by undesired microorganisms, in particular microorganisms present in human skin, such as different kind of bacteria and yeasts.
  • Anti microbial agents comprise inter alia quorum sensing inhibitors and antibiotics, but also other substances toxic for particular microorganisms, such as finely divided silver and detergents.
  • the patient interface may for example have a first member which is connected with a second member, said first member comprising a cushion for contacting a face of the user, and wherein the second member comprises a mask shell for holding the cushion.
  • Said cushion has a skin contacting material (SCM).
  • the skin contacting material (SCM) may be also denominated skin contacting material (SCM) part or sealing flap herein.
  • the skin contacting material (SCM) of the cushion or alternatively said cushion comprises at least one functional material having a predefined functionality and at least one indicator, wherein concentration of the at least one indicator in said cushion correlates with the predefined functionality of said at least one functional material.
  • the functional material may be a constituent of said member.
  • at least a part of the member or the complete member is made of the functional material.
  • Examples of such functional materials being a constituent of said member comprise inter alia a hydrophilic material that absorbs water or a hydrophilic material formed with capillaries as outlined in the instant application.
  • Examples comprise a member made of hydrophilic material formed with capillaries, to which alpha olefin sulfonate and/or a quorum sensing inhibitor has been added.
  • An indicator or a mask wear out indicator may be each kind of chemical substance which may be either colored per se or undergoes a color change upon an external influence.
  • each dye may be used for putting the present invention into practice.
  • the color change of the mask to be used as wear out indicator allows the user visual control and feedback on the mask functionality.
  • a color wheel may be used permitting comparison and facilitating the actual wear out condition and remaining life-span of the mask.
  • the color change may be validated employing digital color measurements.
  • At least one indicator is directed to any number of indicators, such as 1 to 10 indicators, preferred are 5, 4, 3, 2 indicators or 1 indicator.
  • the concentration of said indicator is usually positively correlated with the predefined functionality of said material. This means that any decrease of the predefined functionality in said member, either by washing out, decomposition, (chemical) modification, or any other event causing loss of functionality of said material, involves diminishing of the concentration of the indicator. This decrease in concentration may be usually easily followed by the user and permits a qualitative or quantitative assignment to the actual rate of wear.
  • Said at least one functional material having a predefined functionality and said at least one indicator may be arranged in one or more of the following a skin contacting material (SCM) of the member, a cushion for contacting a face of the user, a forehead support, and a mask shell.
  • SCM skin contacting material
  • the member may be understood as any component of a patient interface, particularly those which are either in direct contact with the skin of the user upon wearing the same or in close vicinity thereto. It will be appreciated that the member is not limited to patient interfaces but may be also employed in other body-worn devices such as head sets.
  • said functional material having a predefined functionality and/or said at least one indicator is inherent in the material forming of one or more of the following the skin contacting material (SCM) of the member, a cushion for contacting a face of the user, a forehead support, and a mask shell.
  • SCM skin contacting material
  • At least one functional material is directed to any number of functional materials, such as 1 to 10 functional materials, preferred are 5, 4, 3, 2 functional materials or 1 functional material.
  • At least one indicator is directed to any number of indicators, such as 1 to 10 indicators, preferred are 5, 4, 3, 2 indicators or 1 indicator.
  • each number of indicators and functional materials may be employed in the present patient interface or present member for patient interfaces.
  • Another alternative is a combination of 1 indicator and 3 functional materials, such as a member made of hydrophilic material formed with capillaries, containing an indicator, such as Fast Green FCF, alpha olefin sulfonate and a quorum sensing inhibitor.
  • an indicator such as Fast Green FCF, alpha olefin sulfonate and a quorum sensing inhibitor.
  • Said skin contacting material represents the part of the member of the patient interface forming the immediate contact between the patient interface and the human skin upon wearing by a user.
  • the skin contacting material (SCM) may have a certain layer thickness of 0.1 to 5 mm, preferably from 0.1 to 4 mm, from 0.1 to 3 mm, from 0.1 to 2 mm, from 0.1 to 1 mm, from 0.1 to 0.5 mm, from 0.1 to 0.4 mm, or from 0.2 to 0.4 mm. More preferred is a layer thickness of 0.3 to 0.4 mm such as 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37 0.38 or 0.39 mm.
  • Said at least one functional material having a predefined functionality and said at least one indicator are usually embedded or evenly distributed in said skin contacting material (SCM). This means that the molecules or function of said at least one functional material having a predefined functionality and said at least one indicator have on average essentially the same distance to each other.
  • said moisture uptake means is a hydrophilic material.
  • the hydrophilic material is preferably a rubber material.
  • the rubber material can be any of silicone, latex, and polybutadiene or other materials as disclosed below.
  • the hydrophilic polymer material e.g. a hydrophilic rubber or elastomeric material
  • may exhibit improved moisture uptake properties e.g. a hydrophilic silicone rubber material, which is capable of taking up more than 5% by weight of water, preferably more than 10% by weight of water, more preferably more than 20% by weight of water, most preferably more than 40% by weight of water, and up to 500% by weight, or up to 200%, or up to 120% by weight, of water after immersion in demineralized water at room temperature for a sufficient time such as 5 days or more to reach saturation.
  • Such water-absorbing rubbery or elastomeric polymer materials may be in the form of a sheet, or a coating adapted to be applied to a substrate, or foam, or a fiber, or any other form suitable for including into a medical or non-medical device where significant water-absorbing properties are desirable.
  • hydrophilic polymer materials e.g. hydrophilic rubber or elastomeric materials, other than a hydrophilic silicone rubber material may be provided. This may be achieved for example by providing a hydrophilic polyurethane.
  • hydrophilic compounds to be mixed into the silicone or polyurethane are for example alpha olefin sulfonate, monomers or pre-polymers including, but are not limited to, glycerol, ethylene glycol derivatives, polyethylene glycol and other hydroxyl function-containing polyol compounds.
  • hydrophilic polymers that can be mixed into the silicone or polyurethane, etc., include, but are not limited to: polyvinylpyrrolidones (usually with a number average molecular weight from 20,000 to 400,000), poly(hydroxyethyl methacrylates), polyethylene glycols (usually with a number average molecular weight from 200 to 10,000), polyvinyl alcohols (usually with a number average molecular weight from 10,000 to 150,000), polyacrylamides, alkali metal poly(meth)acrylates (such as, but not limited to, sodium polyacrylate, potassium polyacrylate, sodium polymethacrylate, potassium polymethacrylate), and mixtures thereof. Still other examples of hydrophilic polymers include hydrophilic polyether block amide copolymers.
  • the hydrophilic polymer material e.g. a hydrophilic rubber or elastomeric material
  • may exhibit improved moisture uptake properties e.g. a hydrophilic silicone rubber material, which is capable of taking up more than 5% by weight of water, preferably more than 10% by weight of water, more preferably more than 20% by weight of water, most preferably more than 40% by weight of water, and up to 500% by weight, or up to 200%, or up to 120% by weight, of water after immersion in demineralized water at room temperature for a sufficient time such as 5 days or more to reach saturation.
  • Such water-absorbing rubbery or elastomeric polymer materials may be in the form of a sheet, or a coating adapted to be applied to a substrate, or foam, or a fiber, or any other form suitable for including into a medical or nonmedical device where significant water-absorbing properties are desirable.
  • hydrophilic silicone rubber materials there is no limitation upon the manufacturing method by which they may be obtained, that is any of the three crosslinking methods briefly mentioned above and further detailed hereinafter may be suitable, depending upon the medical or non-medical application for which the hydrophilic silicone rubber material is intended, and depending the form (e.g. sheet, coating, fiber or foam) in which the water-absorbing silicone rubber material is desired.
  • the present invention relates to hydrophilic silicone-based rubber materials having such high water uptake capacity at preferably room temperature that they can be used for manufacturing skin-friendly materials, in particular skin-contact products with a moisture regulation or moisture management function.
  • the water-absorbing (hygroscopic) silicone-based rubber materials may be suitable for contact with human skin and water containing soft tissues but also hard tissues covered by fluid/water filled viscoelastic films (e.g. tooth pellicle).
  • hydrophilic polymer materials e.g. hydrophilic rubber or elastomeric materials, other than a hydrophilic silicone rubber material may be provided. This may be achieved for example by providing a hydrophilic polyurethane.
  • hydrophilic compounds to be mixed into the silicone or polyurethane are for example alpha oelfin sulfonate, monomers or pre-polymers include, but are not limited to, glycerol, ethylene glycol derivatives, polyethylene glycol and other hydroxyl function-containing polyol compounds.
  • Other examples of hydrophilic polymers that can be mixed into the polymers such as silicone, polyurethane...
  • hydrophilic polymers include, but are not limited to: polyvinylpyrrolidones (usually with a number average molecular weight from 20,000 to 400,000), poly(hydroxyethyl methacrylates), polyethylene glycols (usually with a number average molecular weight from 200 to 10,000), polyvinyl alcohols (usually with a number average molecular weight from 10,000 to 150,000), polyacrylamides, alkali metal poly(meth)acrylates (such as, but not limited to, sodium polyacrylate, potassium polyacrylate, sodium polymethacrylate, potassium polymethacrylate), and mixtures thereof. Still other examples of hydrophilic polymers include hydrophilic polyether block amide copolymers.
  • the hydrophilic material moisture uptaking means may include one or more antibacterial agents, and/or one or more anti fungal agents such as silver compounds, or one or more anti-viral agents such as a microbiocide, all or any of these being for instance present in, or coated onto, any material in contact with the skin of the user.
  • said hydrophilic material is an alpha olefin sulfonate containing/filled silicone rubber.
  • an alpha-olefin sulfonate surfactant into the polymers forming the patient interface, cushion or member may provide a mixture with an increased hydrophilic character which can be used to increase its capacity to hold water.
  • biocompatible polymers such as, but not limited to, silicones, polybutadiene, polybutadiene-containing polymers, polybutadiene -polyethylene oxides copolymers, poly(meth)acrylates, and isobutylene-ethylene glycol copolymers.
  • said anti microbial agent is a quorum sensing inhibitor.
  • the quorum sensing inhibitor may target one or more of the following:
  • Quorum sensing inhibitors are a big class of molecules which work by acting as an inhibitor for intercellular communication between bacteria thereby suppressing the formation of biofilms. Blocking the microbial communication could prevent the expression of many genes involved in the symbiosis of microbes with its own species as well with other species, inhibits biofilm formation, antibiotic production, and expression of virulence factors, etc. Synthetic compounds have also been found to be effective in quenching the quorum sensing system. Said quorum sensing inhibitors exhibit a potential for preventing and treating bacterial infections.
  • quorum sensing inhibitors suitable for use in the present invention comprise halogenated furanone compounds or furanone derivatives in general, but also other nonfuranone quorum sensing compounds are encompassed by the present invention. Halogenated furanone compounds or furanone derivatives are however preferred.
  • R 1 is H, OH or OAc, R 2 and R 3 are independently from each other Br or H, and R 4 is Br or I, preferably R 1 is H, R 2 , R 3 , R 4 are each Br; or R 1 and R 3 are each H, R 2 and R 4 are each Br; or R 1 is OAc, R 2 and R 4 are each Br, R 3 is H; or R 1 is OH, R 2 and R 4 are each Br, R 3 is H; or R 1 is OAc, R 2 is Br, R 3 is H, R 4 is I; or R 1 and R 2 are each H, R 3 and R 4 are each Br; or R 1 is OAc, R 2 , R 3 , R 4 are each Br.
  • said at least one indicator is a colorant.
  • the colorant may be essentially each kind of chemical substance exhibiting a color. It will be appreciated that the intensity of the color depends on the concentration of the colorant as well as its chemical poverties.
  • the functional material having a predefined functionality the colorant may be evenly distributed in said member. In this case the decrease in predefined functionality may be based essentially on the same mechanism like the loss of concentration of said at least one indicator. This means that the material with a predefined functionality may be washed out, i.e. the reason may be a diffusion based mechanism or decomposition. The same holds true for the indicator which is washed out together with the functional material having a predefined functionality or decomposes in parallel to said functional material having a predefined functionality.
  • the colorant may be chemically linked to the functional material having a predefined functionality.
  • the colorant may be associated with the functional material having a predefined functionality either by van der Waals forces or hydrogen bonds. It is also possible that the colorant does not exhibit any inter molecular or intra molecular interaction with the functional material having a predefined functionality.
  • the hydrophilic compound mixed into the polymer such as the alpha olefin sulfonate mixed into the silicone, can be used.
  • Acid Blue 7 (CI 42080, 656840); Acid Blue 80; Acid Yellow 17Alizarine Cyanine Green W.-S., D&C Green No. 5; Allura Red AC, FD&C Red No. 40; Amaranth, Naphthol Red S (E 123); Anthralan Violet 3B; Anthraquinone Dyes, such as Carmine, Alizarine Cyanine Green, Irisol, Acid Blue 80; Azorubine, Carmoisine (E 122); Beetroot Betanin (E 162); Brilliant Acid Green BS, Wool Green S, Lissamin Green BS (E142); Brilliant Black PN (E 151); Brown FK (E 154); Brown HT, Chocolate Brown HT (E 155); Carmine, Cochineal, Carminic Acid (E 120); Erythrosine (E 127); Fast Green FCF, FD&C Green No.
  • Acid Blue 7 (CI 42080, 656840); Acid Blue 80; Acid Yellow 17Alizarine
  • Another group of suitable colorants comprises: Anthocyanin; Enocyanin (E 163); and Methyl Violet B. It has been found that these colorants are particularly suitable for hydrophilic silicone. Said colorants are non-charged or positively charged. They do not form water insoluble products and exhibit low toxicity. Washing of the mask may be performed with cationic detergents.
  • a further group of suitable colorants comprises: all above mentioned dyes; Ribovlavin; and Lactoflavin (E 101i). It has been found that these colorants are particularly suitable for hydrophilic silicone. Said colorants are non-charged, positively or negatively charged. They do not form water insoluble products and exhibit low toxicity. Washing of the mask may be performed with non-ionic detergents.
  • a further group of suitable colorants comprises: Alizarine Cyanine Green F.-S.; Annatto (E 160b); Beta-Apo-8-Carotenal (E 160e); Beta-Apo-8-Ethyl Ester of Carotene Acid(E 160f); Xanthophylls such as Astaxanthin, Lutein (E 161b); Beta-Carotene (E 160a); Canthaxanthin (E 161g); Carotenoids Carotenes (alpha, beta, gamma, E 160a); Ceres Brown B, Fat Brown B; Chlorophyll, Leaf Green (E 140); Heliogen Blue B, Phthalocyanine Blue; Heliogen Green G, Phthalocyanine Green; Indanthrene Brilliant Red R, D&C Red No.
  • colorants preferably permit qualitative or even quantitative indication of the remaining span of life by comparing the actual color of the cushion or member with color wheels or colored diagrams containing in turn indications referring to a time specification.
  • time specification may comprise a time specification in days or weeks, for example one, two, three, four, five, six, seven or eight weeks.
  • time periods may be indicated on the color wheel or colored diagram, such as two to three weeks, three to four weeks, 10 to 20 days, 20 to 30 days, 30 to 40 days, 40 to 50, days, 50 to 60 days, etc.
  • said colorant is a natural or synthetic food dye.
  • Said food dyes may be non-charged or negatively charged (in case of hydrophilic silicone with anionic detergents), non-charged or positively charged (in case of hydrophilic silicone with cationic detergents), non-charged, positively or negatively charged (in case of hydrophilic silicone with non-ionic detergents), non-charged or anionic with tetraalkylammonium counter ions (in case of hydrophobic silicone).
  • said food dye is selected from the group consisting of Allura Red AC, Erioglaucine disodium salt, Tartrazine and Fast Green FCF or combinations thereof.
  • said member is shared in different regions, each of said regions comprising a different indicator.
  • the complete member has the same functional material having a predefined functionality that is shared in different regions.
  • a different indicator or indicators maybe present in each of said region.
  • the regions may have essentially each shape in each form of boundary between each other. For example in the indicators in the boundary area between two regions may be mixed with each other.
  • indicators with complementary colors may be used to obtain a different color in the boundary area, such as a yellowish (brownish) color in the boundary area if a red and a green indicator has been employed. It will be appreciated that the color depends also from the material used for preparing the mask.
  • each of said regions is adapted to indicate the presence of a functional material having a predefined functionality.
  • each of said regions may provide an individual color for one material of having a predefined functionality.
  • said at least one indicator forms a graphical pattern and/or at least one letter on said member.
  • the indicator is present in a surface area of the member which has upon top view the shape of a graphical pattern and/or at least one letter.
  • Graphical patterns may comprise essentially each shape, for example a symbol, a small drawing and/or geometric figures.
  • the at least one letter may be derived essentially from each alphabet. It will be appreciated that different letters may be combined to form an understandable word or message informing the user that e.g. replacement of the member is required.
  • two or more indicators are present.
  • Each of said two or more indicators may form the secondary color different from the primary colors of each of said two or more indicators.
  • the member for the patient interface may, for example, comprise an alpha olefin sulfonate containing silicone rubber as the material with a predefined functionality in the combination of Brilliant Blue FCF and Fast Green FCF. All three compounds belong to the classes of sulfonates and are therefore expected to be removed from the member in essentially a similar speed. Accordingly in the beginning the member will have a turquois color with result of the mixing color from blue and green. In case the alpha olefin sulfonate is washed out essentially the same holds true for the two indicators. Accordingly, member which exceeded its span of life has only the color of the material, e.g. plastic material of the member.
  • an alpha olefin sulfonate containing silicone rubber may be mixed with Brilliant Blue FCF and chlorophylline.
  • Chlorophylline is also a green dye with the consequence that in the beginning the mixing color will be once again turquois. Since chlorophylline has several carbonate groups its solubility in water is essentially higher than that of Brilliant Blue FCF. Accordingly decrease of alpha olefin sulfonate will first result in a color change from turquois to blue and then to colorless.
  • the secondary color is a complementary color.
  • Complementary colors exhibit when combined in correct proportions white or black colors.
  • red and green indicators may be employed.
  • An alternative recites in a combination of a blue and orange indicator.
  • the advantage of employing indicators capable of forming complementary colors recites in that the complementary colors may be very well visible. Therefore, the sensitivity for determining a decrease in predefined functionality of said material is high.
  • said at least one material and said at least one indicator are homogenously or evenly distributed in said member.
  • evenly distributed means that all functions or molecules of the functional material having a predefined functionality and of said indicator have essentially the same distance to each other.
  • agglomerates may be also evenly distributed in the material in the sense that said agglomerates have essentially the same average distance to each other.
  • Homogenous distribution of said at least one material in said at least one indicator within said member may be easily obtained by mixing the starting compounds of said member together with said at least one material in said at least one indicator before hardening of the member.
  • said member is a first member which is connected with a second member through a mechanical release mechanism thereby forming a patient interface for delivering gas to a user.
  • said member further comprises other constituents, such as fillers.
  • the first member may comprise the cushion having the skin contacting material (SCM).
  • the second member comprises the mask shell. This construction facilitates separation of the cushion from the patient interface and thereby washing and in case if required renewal of the same.
  • Fig. 1 shows an example of a mask according to the present invention.
  • the main structural elements of the mask shown in Fig. 1 are generally known.
  • the embodiments according to the present invention are shown in Figs. 2 to 6 .
  • Fig. 1 shall give an overview of the main structural elements comprised in such a mask.
  • the mask is in Fig. 1 in its entirety denoted with reference numeral 10.
  • the mask 10 in the following also referred to as patient interface 10, is typically used in pressure support systems (CPAP systems) that supply a flow of gas to the airway of a patient 50.
  • CPAP systems pressure support systems
  • Such patient interfaces are well-known and are mostly worn on the head using a strap system 12 around the patient's head to hold the mask 10 in place around the airway entry features of the human face.
  • the patient interface 10 typically comprises a rigid or semi-rigid mask shell 14 to which the head gear/strap system 12 is attached.
  • the mask shell 14 is usually made of a rigid or semi-rigid material, such as e.g. plastic, polycarbonate or silicone. However, also other materials are generally conceivable.
  • the mask shell 14 serves as a holding frame for holding a flexible or soft cushion/mask flap 16.
  • the cushion/mask flap 16 engages the patient's face when the mask/patient interface 10 is attached to the patient's face during use. It serves as mask-to-patient interface.
  • These cushions 16 are usually made of silicon or comprise one or more gel pads in order to establish a soft contact on the patient's face.
  • a further function of these cushions 16 is the sealing of the interior of the patient interface 10 to the exterior surrounding in order to prevent unwanted air leaks between the patient interface 10 and the patient's face when pressure is supplied to the patient's airway.
  • the shape of the cushion/mask flap 16 is thereto preferably adapted to the shape of the user's face.
  • the illustrated example refers to a so-called full-face mask 10, wherein the cushion/mask flap 16 surrounds the nose and mouth of the user 50.
  • These full-face masks 10 often comprise an additional cushion support 18, also referred to as forehead support 18, which may be integrally connected to the mask shell 14, and which is arranged to engage the forehead of the patient 50.
  • the additional cushion support/forehead support 18 mainly serves to balance the forces that the mask 10 exerts onto the face of the patient 50 and to mechanically stabilize the mask shell 14 as well as to serve for a correct and comfortable fit of the mask 10.
  • a gas supplying hose (not shown) is usually connected to a connection interface 20 that is preferably attached to or integrated into the mask shell 14.
  • the example of the patient interface 10 shown in Fig. 1 refers to a so-called full-face mask. It is to be noted that this type of mask is herein included only for illustrative reasons in order to explain the core features of the present invention and make them apparent. However, the present invention is not restricted to any certain type of mask. The present invention may also be applied, for example, for nasal masks, oral masks, total face masks or nasal pillows.
  • Fig. 2 shows a first embodiment of the patient interface 10 according to the present invention that overcomes the above-mentioned disadvantages of masks according to the state of the art.
  • Patient interface 10 comprises a first member 22 and a second member 24 that can be connected to each other through a mechanical release mechanism.
  • the first member 22 comprises in this example the cushion/sealing flap 16 or is realized as the cushion/sealing flap 16.
  • the first member 22 exhibits also the skin contacting material (SCM) 36 touching the skin of the user when the mask is used.
  • the first member 22 contains said at least one functional material having a predefined functionality and said at least one indicator (not shown).
  • the second member 24 comprises the mask shell 14 or is realized as the mask shell 14.
  • first and second members 22, 24 may also refer to other parts of the mask 10 that can be, but do not have to be releasably connected to each other, e.g. also to the air supplying hose (not shown) and a connection interface 20 (see Fig. 1 ), i.e. not necessarily as illustrated to the cushion/mask flap 16 and the mask shell 14.
  • Fig. 2a shows the disassembled mask 10 wherein the cushion/mask flap 16 or the first member 22 is separated or unconnected from the mask shell 14 or second member 24.
  • the skin contacting material (SCM) is indicated by reference number 36.
  • Fig. 2b illustrates the situation in which the two members 22, 24 of the patient interface 10 (the cushion/mask flap 16 and the mask shell 14) are connected to each other, i.e. a condition wherein the cushion/mask flap 16 is inserted into the mask shell 14.
  • Fig. 3-11 refer all patient interfaces 10 having inter alia the cushion 16 with the skin contacting material (SCM) 36 formed or made thereon which applies likewise to the forehead support 18. It will be appreciated that this is no limitation to a particular construction, but rather member 22, cushion/mask flap 16 and skin contacting material (SCM) 36 may form a single piece. Alternatively, member 22 and cushion/mask flap 16 may form a single piece, whereas the skin contacting material (SCM) 36 is formed or made thereon. Still alternatively, cushion/mask flap 16 and skin contacting material (SCM) 36 may form a single piece, whereas the member 22 is formed or made thereon to provide connection to the mask shell 14. Still alternatively, member 22, cushion/mask flap 16 and skin contacting material (SCM) 36 are all discrete elements which may be connected to each other.
  • the skin contacting material (SCM) 36 may be formed or made on the forehead support 18.
  • the skin contacting material (SCM) 36 and the forehead support 18 may be one piece. It will be appreciated that the forehead support 18 may be omitted.
  • the functional material 32, 34 having a predefined functionality pertains essentially to each kind of active compound, such as drugs or prodrugs, including of which may be beneficial for the user upon wearing the member/ patient interface.
  • Two preferred examples of materials 32, 34 having a predefined functionality are (i) moisture uptake means, such as hydrophilic materials capable of taking up and/or absorbing water and which may be either added to the material forming the member or which may be the material used for preparing the member or at least part thereof, and (ii) anti microbial agents. It will be understood that the representation of e.g. hydrophilic material by circles in the figures is not to be understood as limiting but rather schematically highlights the function of the e.g. hydrophilic material.
  • the moisture uptake means may refer to any material capable of taking up or adsorbing moisture and may comprise for example a hydrophilic material or a hydrophobic material.
  • the hydrophilic silicone may be processed out of a mixture of a standard silicone and an addition of alpha olefin sulfonate.
  • the anti microbial agents may prevent bacteria growth and a biofilm formation on the skin contacting material (SCM) 36, which could likewise lead to skin infections, inflammation or other bacteria-induced infections such as pulmonary infections or infections of the respiratory system through biofilms present on mask materials and entering the respiratory system during use of CPAP.
  • Anti microbial agents comprise inter alia quorum sensing inhibitors and antibiotics, but also other substances toxic for particular microorganisms, such as finely divided silver. Quorum sensing inhibitors are particularly preferred in the present embodiments. Quorum sensing inhibitors block the microbial communication and may prevent the symbiosis of microbes with its own species as well as with other species and regulates the expression of genes involved in biofilm formation, antibiotic production, expression of virulence. Examples of particularly preferred quorum sensing inhibitors comprise halogenated furanone compounds or furanone derivatives in general.
  • Fig. 3 represents another view on the mask 10 wherein the skin contacting material (SCM) 36 can be seen more in detail.
  • the material skin contact are 36 is in this example made on the cushion/mask flap 16.
  • the skin contacting material (SCM) 36 is made on the forehead support 18.
  • a functional material 32 having a predefined functionality may be employed in the skin contacting material (SCM) 36 of the cushion/mask flap 16 and/or the forehead support 18 .
  • a functional material 32 having a predefined functionality may be employed.
  • the functional material 32 may be a compound added to the material forming said member 22.
  • the functional material 32 may be a constituent of said member, i.e.
  • At least one indicator 30 may be employed in the skin contacting material 36.
  • the concentration of said at least one indicator 30 is preferably correlative with the predefined functionality of said at least one functional material 32. In other words, this means that as soon as the material 32 having a predefined functionality is reduced, washed out, or looses its functionality the at least one indicator will be reduced or lost as well or at least changes its visual appearance. In this way the user may receive a visual indication by means of the at least one indicator 30 if the predefined functionality of said at least one functional material 32 is reduced or completely lost, e.g. due to wear-out of patient interface 10.
  • said at least functional material 32 is a hydrophilic material, such as hydrophilic silicone processed out of a mixture of standard silicone and addition of alpha olefin sulfonate
  • the said at least one indicator 30 is one of the colorants outlined above, such as Fast Green FCF.
  • the functional material 32 improves the moisture uptake behavior of the patient interface 10 which is specifically important for improving the comfort of the patient 50 and for preventing a moisture accumulation at the skin contact area 36, which could lead to skin irritations and/or skin damages.
  • the at least one indicator or colorant 30 helps to visually indicate the user that one or both material have lost their function at least to some extent. Thereby the user receives a feedback when to replace the patient interface 10 or at least parts of it, e.g. the cushion/mask flap 16.
  • any combination of one or more of the above mentioned materials 32 having a predefined functionality may be encompassed by the present invention and are also suitable to put the present invention into practice.
  • the functional material 32 may be a compound added to the material forming said member 22.
  • the functional material 32 may be a constituent of said member, i.e. a part of the member 22 or the complete member 22 is made of the functional material.
  • the indicator(s) 30 employed. Further examples for suitable functional materials 32 and indicators 30 have been mentioned in the summary of the invention.
  • Fig. 4 schematically illustrates the distribution of functional materials within the skin contacting material (SCM) 36 shown in Fig. 3 .
  • Indicator molecules 30 and the functional material 32 having a predefined functionality are evenly distributed or embedded in the material forming the skin contacting material (SCM) 36 which is the same like the material forming the cushion/mask flap 16 or first member 22 and which may be a silicone rubber.
  • Fig. 5 and 6 corresponds essentially to Fig. 3 and 4 .
  • functional material 32 another functional material 34 has been employed (see Fig. 5 ) which is a quorum sensing inhibitor which may be mixed into the polymer, such as a hydrophobic silicone, which is present at least in the skin contacting material (SCM) 36.
  • the indicator 30 may be the same as for the first embodiment, i.e. Fast Green FCF. It will be however appreciated that based on the selection of another functional material 34 another indicator 30 may be employed.
  • Fig. 6 indicates that functional material 34 and indicator 30 are homogenously distributed within the skin contacting material (SCM) 36.
  • Fig. 7 and 8 corresponds essentially to Fig. 3 and 4 .
  • Functional material 32 is a hydrophilic silicone processed out of a mixture of standard silicone and addition of alpha olefin sulfonate, but may be however also a quorum sensing inhibitor mixed into a polymer or a combination of standard silicone, alpha olefin sulfonate and quorum sensing inhibitor.
  • the indicator 30 may be the same as for the first and second embodiment or different.
  • Indicator 28 differs from indicator 30. In the present example the indicator 30 is Fast Green FCF and the indicator 28 is Allura Red AC.
  • Fig. 8 indicates that functional material 32 and indicators 28/30 are homogenously distributed within the skin contacting material (SCM) 36.
  • SCM skin contacting material
  • the embodiment shown in Fig. 9 indicates two regions 40, 42 made in the skin contacting material (SCM) of the cushion/mask flap 16 or first member 22.
  • the material of the skin contacting material (SCM) 36, the cushion/mask flap 16 or first member 22 may be once again a silicone rubber.
  • Sodium alpha-olefin sulfonate may be employed 30 as functional material having a predefined functionality.
  • the first indicator may be Allura Red AC and a second indicator may be Fast Green FCF.
  • the first indicator is present in the region 40 exclusively whereas the second indicator 30 is present in the other region 42 exclusively. It will be appreciated that the indicators and materials having a predefined functionality serve for illustrating purposes only.
  • Figs. 10a show that in the first region 40 indicated in Fig. 9 for example Allura Red AC as first indicator 28 and for example sodium alpha-olefin sulfonate molecules forming the material 32, 34 having a predefined functionality are employed.
  • the molecules of the indicator 28 and of the material 32, 34 having a predefined functionality may be evenly distributed or embedded in the material forming the skin contacting material (SCM) 36, cushion/mask flap 16 or first member 22.
  • SCM skin contacting material
  • Fig. 10b shows that a second indicator 30 and material 32, 34 having a predefined functionality are present in the region 42.
  • the molecules 30 and 30 may be evenly distributed or embedded within the material forming the skin contacting material (SCM) 36, cushion/mask flap 16 or first member 22.
  • the exemplary use of two indicators of complementary colors (red and green) in different regions 40, 42 of the skin contacting material (SCM) 36 permits improved possibility to the user to recognize when the material 32, 34 having a predefined functionality is essentially washed out of the skin contacting material (SCM) 36, cushion/mask flap 16 or first member 22.
  • the use of two color indicators, especially the use of two complementary colors may be more easily prosecuted by employing a color wheel (not shown). It may be of particular advantage to employ indicators of complementary colors which are washed out at different speeds.
  • the skin contacting material (SCM) 36 may be provided with a symbol 50 and letters 52 forming the word "replaced". Symbol 50 and message 52 are only visible in case the cushion/mask flap 16 or first member 22 needs to be replaced. This may be obtained essentially in two ways. The first resides in forming the symbol 50 and/or a message 52 below the surface of the skin contacting material (SCM), for example in depth of up to 6 mm.
  • the symbol 50 and/or a message 52 may be made at other distances from the surface, for instance 50 ⁇ m to 6 mm, 1 to 5 mm, 1 to 4 mm, 2 to 4 mm and 3 to 4 mm, 500 ⁇ m to 1 mm, 200 ⁇ m to 500 ⁇ m, 100 ⁇ m to 300 ⁇ m, 50 ⁇ m to 100 ⁇ m.
  • the skin contacting material (SCM) 36, cushion/mask flap 16 or first member 22 is provided with a material having a predefined functionality and an indicator. The concentration of the indicator as well as its color are chosen in a manner that its color completely covers the symbol 50 and message 52.
  • the concentration of the indicator decreases in parallel/simultaneously to the predefined functionality of said functional material which is reduced either due to washing out or decomposition. If the concentration of the indicator is low enough and its color has disappeared to a sufficient degree symbol 50 and message 52 will be visible to the user and indicate replacement need due functionality change.
  • the entire skin contacting material (SCM) 36, cushion/mask flap 16 or first member 22 may consist of the material having a predefined functionality.
  • Symbol 50 and message 52 may be made with one or more indicators. In case only one indicator is used disappearance of the symbol 50 and message 52 occurs due to reduced concentration of the indicator which correlates with the loss of the predefined functionality of said functional material. Disappearance of the symbol 50 and message 52 thereby indicates that replacement is required.
  • the use of two indicators of different solubility may be used to indicate by a color change of the symbol 50 and message 52 that replacement is required.
  • First and second indicator originally form a mixing color (third color). Due to accelerated washing out of the indicator of higher solubility in water the second indicator remains in the material, having a different color than the mixing color.
  • hydrophilic silicone is processed to form a cushion.
  • the hydrophilic silicone is processed out of a mixture of a standard silicone and an addition of alpha olefin sulfonate.
  • the hydrophilic silicone cushion takes up moisture from the patient's skin and improves in this manner patient comfort and reduces risk for red mark formation.
  • the indicator is a color change indicator.
  • a hydrophilic silicone cushion employed may be prepared from a formulation with Elastosil LR3004/40: 12 g of sodium alpha-olefin sulfonate (BIO-TERGE® AS-90 BEADS, Stepan Company Northfield, Illinois, United States) was mixed 3 to 4 times with 7 g of (1:1) ethanol and water. Afterwards 19 g of Elastosil LR 3004/40 A (Wacker Silicones, Germany) were added and mixed for two times. Subsequently water and ethanol were removed until about 0.5 g of the water/ethanol phase still remained resulting in good mixing with component B and no agglomerates. The solvents were removed under vacuum and at a temperature of 70 to 80° C for several hours until the solvents were removed to the desired degree. The solution was gently mixed during evaporation.
  • Elastosil 3004/40B 26 g were added and mixed two to three times until a homogenous mixture was obtained.
  • the ratio A:B was 1:1,37 and the ratio (A+soap):B is 1.19:1.
  • the mixture was processed in a mold for 20 min at a temperature between 130 and 140° C. If required post-curing under vacuum at a temperature of about 130° C for one hour may be employed.
  • Elastosil 3004/40B 26 g were added and mixed two to three times until a homogenous mixture was obtained.
  • the ratio A:B was 1:1,37 and the ratio (A+soap):B is 1.19:1.
  • the mixture was processed in a mold for 20 min at a temperature between 130 and 140° C. If required post-curing under vacuum at a temperature of about 130° C for one hour may be employed.
  • the silicone precursor material is a two component system that was normally mixed in a 1:1 weight ratio of two components A and B.
  • the A component consists of a silicone pre-polymer bearing reactive vinyl groups and a platinum catalyst.
  • the B component consists of a silicone pre-polymer bearing reactive vinyl groups and a pre-polymer bearing Si-H groups.
  • the commercial sodium alpha-olefin sulfonate added to the silicone precursors A+B is thus amounting to 27.5 weight% of silicone precursor (A+B) weight ((weight sodium alpha-olefin sulfonate/weight silicone A+B) ⁇ 100).
  • the mixing ratio of this system for component A to B was 1 to 1.3.
  • Material samples were prepared by pressure molding at 130°C for 10 to 15 minutes at 711 psi (approximately 49 bar). If required, post curing under vacuum at a temperature of about 130° C for one hour may be employed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Anesthesiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Materials For Medical Uses (AREA)
  • Respiratory Apparatuses And Protective Means (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Radiation-Therapy Devices (AREA)

Claims (16)

  1. Elément (22) pour une interface patient (50), ledit élément (22) comprenant :
    - au moins un matériau fonctionnel (32, 34) ayant une fonctionnalité prédéfinie, et
    - au moins un indicateur (28, 30),
    dans lequel une concentration dudit au moins un indicateur (28, 30) dans ledit élément (22) est en corrélation avec la fonctionnalité prédéfinie dudit au moins un matériau fonctionnel (32, 34), dans lequel ledit au moins un matériau fonctionnel (32, 34) et ledit au moins un indicateur (28, 30) sont agencés dans un matériau en contact avec la peau (SCM) (36) ; caractérisé en ce que ledit au moins un matériau fonctionnel (32, 34) comprend un moyen d'absorption d'humidité et/ou un agent antimicrobien.
  2. Élément (22) pour une interface patient selon la revendication 1, dans lequel ledit moyen d'absorption d'humidité est un matériau hydrophile.
  3. Élément (22) pour une interface patient selon la revendication 2, dans lequel ledit matériau hydrophile est un caoutchouc de silicone contenant du sulfonate d'alpha-oléfine.
  4. Élément (22) pour une interface patient selon la revendication 1, dans lequel ledit agent antimicrobien est un inhibiteur de détection de quorum.
  5. Élément (22) pour une interface patient selon la revendication 1, dans lequel ledit au moins un indicateur (28, 30) est un colorant.
  6. Élément (22) pour une interface patient selon la revendication 5, dans lequel ledit colorant est un colorant alimentaire naturel ou synthétique.
  7. Élément (22) pour une interface patient selon la revendication 6, dans lequel ledit colorant alimentaire est choisi dans le groupe comprenant le rouge Allura AC, le sel disodique d'érioglaucine, la tartrazine et le vert rapide FCF, ou des combinaisons de ceux-ci.
  8. Élément (22) pour une interface patient selon la revendication 1, dans lequel ledit élément (22) est partagé en différentes régions (40, 42), chacune desdites régions (40, 42) comprenant un indicateur différent (28, 30).
  9. Élément (22) pour une interface patient selon la revendication 8, dans lequel chacune desdites régions (40, 42) est adaptée pour indiquer la présence d'un matériau fonctionnel (32, 34).
  10. Élément (22) pour une interface patient selon la revendication 1, dans lequel ledit au moins un indicateur (28, 30) forme un motif graphique (50) et / ou au moins une lettre (52) sur ledit élément (22).
  11. Élément (22) pour une interface patient selon la revendication 1, dans lequel deux indicateurs (28, 30) ou plus sont présents, dans lequel lesdits deux indicateurs (28, 30) ou plus forment une couleur secondaire différente des couleurs primaires de chaque desdits deux indicateurs (28, 30) ou plus.
  12. Élément (22) pour une interface patient selon la revendication 11, dans lequel la couleur secondaire est une couleur complémentaire.
  13. Élément (22) pour une interface patient selon la revendication 1, dans lequel ledit au moins un matériau fonctionnel (32, 34) et ledit au moins un indicateur (28, 30) sont répartis uniformément dans ledit élément (22).
  14. Élément (22) pour une interface patient selon la revendication 1, dans lequel ledit élément est un premier élément (22) qui est connecté à un second élément (24) par un mécanisme de libération mécanique, en formant ainsi une interface patient pour délivrer un gaz à un utilisateur (50).
  15. Élément pour une interface patient selon la revendication 1, dans lequel le matériau en contact avec la peau fait partie d'un coussin (16) destiné à entrer en contact avec un visage de l'utilisateur (50), un support frontal (18) ou une coque de masque (14).
  16. Interface patient destinée à délivrer du gaz à un utilisateur (50) comprenant l'élément (22) selon la revendication 1.
EP14811920.9A 2013-12-20 2014-12-15 Interface de patient Active EP3082924B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14811920.9A EP3082924B1 (fr) 2013-12-20 2014-12-15 Interface de patient

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13198893 2013-12-20
PCT/EP2014/077665 WO2015091304A1 (fr) 2013-12-20 2014-12-15 Interface patient
EP14811920.9A EP3082924B1 (fr) 2013-12-20 2014-12-15 Interface de patient

Publications (2)

Publication Number Publication Date
EP3082924A1 EP3082924A1 (fr) 2016-10-26
EP3082924B1 true EP3082924B1 (fr) 2019-11-13

Family

ID=49880521

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14811920.9A Active EP3082924B1 (fr) 2013-12-20 2014-12-15 Interface de patient

Country Status (7)

Country Link
US (1) US10751495B2 (fr)
EP (1) EP3082924B1 (fr)
JP (1) JP2016537141A (fr)
CN (1) CN106061534B (fr)
BR (1) BR112016013881A2 (fr)
RU (1) RU2682476C1 (fr)
WO (1) WO2015091304A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD751188S1 (en) * 2013-03-27 2016-03-08 ResMes Limited Patient interface
EP3763412B1 (fr) * 2013-07-29 2024-09-25 ResMed Pty Ltd Échangeur de chaleur et d'humidité destiné à une interface patient
BR112016013881A2 (pt) 2013-12-20 2017-08-08 Koninklijke Philips Nv Membro para interface com um paciente, e interface com um paciente para a liberação de gás para um usuário
EP3383506A4 (fr) 2015-12-03 2019-08-21 Honeywell International Inc. Unité annulaire pour gestion de l'humidité dans un masque respiratoire
WO2018183389A1 (fr) 2017-03-28 2018-10-04 Allied Bioscience, Inc. Revêtements antimicrobiens pour instruments médicaux et dispositifs médicaux
US20210308495A1 (en) * 2020-04-02 2021-10-07 ReadyDock, Inc. Face mask system with condition indicator
US20230149574A1 (en) 2020-09-16 2023-05-18 Ian Leibowitz Method and Apparatus for Sanitization of Hand Coverings
US11123584B1 (en) 2020-10-05 2021-09-21 Iowa State University Research Foundation, Inc. Personal protective anti-viral face mask
EP4356358A1 (fr) 2021-06-18 2024-04-24 Milwaukee Electric Tool Corporation Système de zone interdite
EP4316558A1 (fr) * 2022-08-03 2024-02-07 PARI GmbH Spezialisten für effektive Inhalation Masque d'inhalation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131001A2 (fr) * 2011-03-29 2012-10-04 Map Medizin-Technologie Gmbh Coussin pour interface patient

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155358A (en) 1976-12-13 1979-05-22 Minnesota Mining And Manufacturing Company Respirator
US4488547A (en) * 1982-09-07 1984-12-18 Kenneth R. Bowers, Jr. Face mask
US5219341A (en) * 1991-12-20 1993-06-15 Kimberly-Clark Corporation Sanitary napkin with a faster transverse wicking absorbent layer to indicate the approach of maximum fluid capacity
JPH07315383A (ja) 1994-05-25 1995-12-05 Shin Etsu Chem Co Ltd ２種の液体収容用容器及び２種の液体が左右分離した容器
US7204250B1 (en) 1999-12-16 2007-04-17 Compumedics Limited Bio-mask
US7069932B2 (en) * 2002-09-06 2006-07-04 Ric Investments, Llc. Patient interface with forehead support system
US9072852B2 (en) * 2004-04-02 2015-07-07 Fisher & Paykel Healthcare Limited Breathing assistance apparatus
NZ581715A (en) 2005-08-22 2010-03-26 Compumedics Ltd Mask assembly
JP2007127422A (ja) 2005-10-31 2007-05-24 Toray Ind Inc 被検物質の測定方法
NZ570220A (en) * 2006-03-01 2011-10-28 Resmed Ltd Reminder system on CPAP mask to provide a reminder after a predeterminded amount of time, relating to servicing
CN101394887A (zh) * 2006-03-01 2009-03-25 雷斯梅德有限公司 用于提醒用户更换和/或保养cpap设备和/或其部件的方法和设备
US8236216B2 (en) * 2006-07-06 2012-08-07 Airway Technologies, Llc System and method for forming a custom medical mask using an orientation device
US8297285B2 (en) 2006-07-28 2012-10-30 Resmed Limited Delivery of respiratory therapy
TWI391658B (zh) * 2006-12-08 2013-04-01 Wei Fang Su 時間歷程指示裝置、其配方及其形成方法
EP2481435B1 (fr) * 2006-12-15 2016-02-24 ResMed Ltd. Administration d'une thérapie respiratoire
US7913640B2 (en) * 2007-11-09 2011-03-29 Kimberly-Clark Worldwide, Inc. Moisture indicator for heat and moisture exchange devices
EP2222359A4 (fr) 2007-12-05 2014-03-12 Svip 7 Llc Dispositifs et procédés de traitement de troubles respiratoires du sommeil
CN106039505A (zh) 2008-06-04 2016-10-26 瑞思迈有限公司 患者接口系统
AU2009257361A1 (en) * 2008-06-12 2009-12-17 3M Innovative Properties Company Biocompatible hydrophilic compositions
US9132250B2 (en) * 2009-09-03 2015-09-15 Breathe Technologies, Inc. Methods, systems and devices for non-invasive ventilation including a non-sealing ventilation interface with an entrainment port and/or pressure feature
CN102655953B (zh) * 2009-12-17 2015-09-16 3M创新有限公司 磺酸根官能涂层和方法
US8430053B2 (en) * 2010-09-30 2013-04-30 Temptime Corporation Color-changing emulsions for freeze indicators
US20140303070A1 (en) * 2010-12-08 2014-10-09 Danmarks Tekniske Universitet Process for the manufacture of ajoene derivatives
TWI491876B (zh) * 2010-12-31 2015-07-11 Ind Tech Res Inst 濕度指示卡及其製造方法
WO2013001438A1 (fr) 2011-06-30 2013-01-03 Koninklijke Philips Electronics N.V. Produit en contact avec la peau doté d'un contrôle de l'humidité et du microclimat
EP2726129A1 (fr) * 2011-06-30 2014-05-07 Koninklijke Philips N.V. Dispositif interface utilisateur fournissant une fonctionnalité améliorée de répartition de la charge
WO2013011478A1 (fr) 2011-07-21 2013-01-24 Svip 7 Llc Dispositifs et procédés de traitement de respiration affectée par des troubles du sommeil
BR112014016633B1 (pt) * 2012-01-04 2021-12-21 The Procter & Gamble Company Estruturas fibrosas com múltiplas regiões contendo agente ativo e método para tratar um artigo de tecido em necessidade de tratamento
US9820515B2 (en) * 2012-04-06 2017-11-21 Kenneth E. Crockett, JR. Apparel with thermochromic dyes for monitoring and optimizing exercise performance
US20140005605A1 (en) * 2012-06-28 2014-01-02 Pacesetter, Inc. Use of quorum sensing inhibitors and biofilm dispersing agents for controlling biofilm-associated implantable medical device related infections
US9535043B2 (en) * 2013-05-31 2017-01-03 Empire Technology Development Llc Color change indicator of biofilm formation
BR112016013881A2 (pt) 2013-12-20 2017-08-08 Koninklijke Philips Nv Membro para interface com um paciente, e interface com um paciente para a liberação de gás para um usuário

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012131001A2 (fr) * 2011-03-29 2012-10-04 Map Medizin-Technologie Gmbh Coussin pour interface patient

Also Published As

Publication number Publication date
CN106061534B (zh) 2019-06-07
JP2016537141A (ja) 2016-12-01
WO2015091304A1 (fr) 2015-06-25
RU2682476C1 (ru) 2019-03-19
US20160317771A1 (en) 2016-11-03
US10751495B2 (en) 2020-08-25
EP3082924A1 (fr) 2016-10-26
BR112016013881A2 (pt) 2017-08-08
CN106061534A (zh) 2016-10-26

Similar Documents

Publication Publication Date Title
EP3082924B1 (fr) Interface de patient
EP2311504B1 (fr) Couverture des plaies comportant du dihydrochlorure d'octénidine pour l'antisepsie de points d'insertion de cathéter
CN103796704B (zh) 用于将抗微生物剂递送到经皮导管中的装置
US10022476B2 (en) Drug releasing medical catheters, tubes, and devices
Holekamp et al. Vitrectomy surgery increases oxygen exposure to the lens: a possible mechanism for nuclear cataract formation
JP6586084B2 (ja) 時間による色変化表示を伴う器具、インジケータ、方法、およびキット
US20230244090A1 (en) Carbon Dioxide Sensing Color Changeable Dyes For Indicating Exposure, Methods of Making and Using Such Dyes, and Apparatuses Incorporating Such Dye
CN107530468A (zh) 局部减少微生物皮肤菌群的方法
CN105407896B (zh) 缓释的地塞米松在白内障手术后的炎症中的应用
CN104080505B (zh) 将药物分子嵌入医用导管或管的系统、器械和方法
CN102293697A (zh) 一种眼保护贴的制备工艺和用途
JP5963744B2 (ja) 薬剤組成物塗布デバイス
US20140350488A1 (en) Drug delivery system
CN107921283A (zh) 包括阿来西定的伤口护理产品
JPWO2018097031A1 (ja) 内境界膜剥離モデルおよびその利用
AU2014274943A1 (en) Prophylactic dressing and use of same in the prevention of infection
EP1401424B1 (fr) Composes de carbamate destines a la prevention ou au traitement de troubles psychotiques
CN109107021A (zh) 一种可防止尿路感染的导尿管
JP7032618B2 (ja) 動物用コンタクトレンズ
EP2691085A1 (fr) Composition filmogène pour une libération prolongée dépendant du ph de l'agent actif
WO2009151268A2 (fr) Écarteur buccal à usage dentaire
CA3114087A1 (fr) Systeme de masque avec indicateur de condition
US20070068517A1 (en) Composition for use with artificial airway devices
BR102020016356A2 (pt) Fita de vedação para equipamento de proteção individual facial de uso médico, industrial e sanitário e protetor facial contra resíduos tóxicos
Walton Lessons from the Drosophila microbiota

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20160720

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170629

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20190605

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1201028

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191115

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014056852

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: KONINKLIJKE PHILIPS N.V.

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191113

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200313

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200213

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200213

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200214

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200313

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014056852

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1201028

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191113

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20200814

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191215

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191231

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20141215

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191113

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231219

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231226

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231227

Year of fee payment: 10